Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | PTGES | O14684 | 1/20 | 0.65 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | CASP7 | P55210 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | DHODH | Q02127 | 6/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | F7 | P08709 | 1/20 | 0.47 |
| ▸ | F3 | P13726 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31716536 | 0.88 | ALDH1A1 (0.51) | ALDH1A1PTGESALOX5CYP2C9HPGD | |
| SCHEMBL22468804 | 0.84 | ALDH1A1 (0.67) | ALDH1A1PTGESALOX5CYP2C9HPGD | |
| SCHEMBL30120641 | 0.83 | ALDH1A1 (0.65) | ALDH1A1PTGESALOX5CYP2C9HPGD | |
| SCHEMBL11668861 | 0.83 | ALDH1A1 (0.65) | ALDH1A1PTGESALOX5CYP2C9HPGD | |
| SCHEMBL24840868 | 0.81 | DHODH (0.65) | ALDH1A1PTGESALOX5CYP2C9HPGD | |
| SCHEMBL30717931 | 0.81 | DHODH (0.65) | ALDH1A1PTGESALOX5CYP2C9HPGD | |
| SCHEMBL29157289 | 0.81 | NPC1 (0.50) | ALDH1A1PTGESALOX5CYP2C9HPGD | |
| SCHEMBL5015458 | 0.79 | RXFP1 (0.57) | ALDH1A1HPGDHSD17B10DHODHKMT2A | |
| SCHEMBL8703497 | 0.79 | EPRS1 (0.58) | ALDH1A1PTGESALOX5CYP2C9HPGD | |
| SCHEMBL2655065 | 0.79 | ALDH1A1 (0.63) | ALDH1A1HPGDHSD17B10DHODHKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144812-A1 | QUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | Epizyme, Inc. (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220144812-A1 | QUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | Epizyme, Inc. (US) | 2022-05-12 | — | — | US | disclosed |
| EP-3946623-A1 | QUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | Epizyme Inc (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-113891749-A | Quinoline derivatives and their use for the treatment of cancer | 埃皮齐梅股份有限公司 | 2022-01-04 | — | — | CN | disclosed |
| WO-2020198567-A1 | QUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | Epizyme, Inc. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020198567-A1 | QUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | Epizyme, Inc. (US) | 2020-10-01 | — | — | WO | disclosed |
| EP-2836483-B1 | ANTI-MALARIAL AGENTS | MERCK PATENT GMBH (DE) | 2016-07-27 | — | — | EP | disclosed |
| EP-2836483-B1 | ANTI-MALARIAL AGENTS | MERCK PATENT GMBH (DE) | 2016-07-27 | — | — | EP | disclosed |
| CN-104302624-B | Antimalarial agent | MERCK PATENT GMBH (DE) | 2016-01-13 | — | — | CN | disclosed |
| US-9115088-B2 | Anti-malarial agents | MERCK PATENT GMBH (DE) | 2015-08-25 | — | — | US | disclosed |
| US-20150045354-A1 | Anti-Malarial Agents | MERCK PATENT GMBH (DE) | 2015-02-12 | — | — | US | disclosed |
| US-20150045354-A1 | Anti-Malarial Agents | MERCK PATENT GMBH (DE) | 2015-02-12 | — | — | US | disclosed |
| CN-104302624-A | Anti-malarial agents | UNIV DUNDEE | 2015-01-21 | — | — | CN | disclosed |
| WO-2013153357-A1 | ANTI-MALARIAL AGENTS | UNIVERSITY OF DUNDEE (GB) | 2013-10-17 | — | — | WO | disclosed |
| WO-2013153357-A1 | ANTI-MALARIAL AGENTS | UNIVERSITY OF DUNDEE (GB) | 2013-10-17 | — | — | WO | disclosed |
| CN-1193016-C | Process for synthesizing inhibitor of phosphatidase A2 | UNIV BEIJING (CN) | 2005-03-16 | — | — | CN | disclosed |
| CN-1502609-A | Process for synthesizing inhibitor of phosphatidase A2 | 北京大学 | 2004-06-09 | — | — | CN | disclosed |
| CN-1067684-C | Imidazo [1,5-1] quinolines for treatment of anxiety and sleep disorders | PHAMACIA UPJOHN CO (US) | 2001-06-27 | — | — | CN | disclosed |
| WO-1997000074-A1 | USE OF IMIDAZO[1,5-a]QUINOLONES AS NEUROPROTECTIVE AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1997-01-03 | — | — | WO | disclosed |
| CN-1135753-A | Imidazo [1, 5-a ] quinolines for the treatment of anxiety and sleep disorders | UPJOHN CO (US) | 1996-11-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045354-A1 | Anti-Malarial Agents | PRMT7, MRPS7, RAB7A | ALDH1A1 2166/4885PTGES 2427/4885ALOX5 2485/4885 |
| US-20220144812-A1 | QUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | TP53, MCL1, COQ8A | ALDH1A1 1709/4885PTGES 3465/4885ALOX5 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.